ReviewChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014
Targets and molecular mechanisms of triptolide in cancer therapy.
Review in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review.Journal of translational medicine · 2025Pooled it
- Active ingredients and molecular targets of Tripterygium wilfordii against colorectal cancer: network pharmacology, molecular docking, molecular dynamics simulations and in vitro evaluation.Journal of computer-aided molecular design · 2026Article
- Harnessing nanoparticles to unlock the therapeutic potential of triptolide in cancer treatment.Medical oncology (Northwood, London, England) · 2026Review
- IRAK4 Regulates NF-κB signaling to suppress CD8 + T cell activity and promote immune evasion in glioblastoma development.Cancer immunology, immunotherapy : CII · 2026Article
- Triptolide targetsFrontiers in pharmacology · 2026Article
- Antitumor natural products targeting mitochondrial NADH: ubiquinone oxidoreductase (complex I): a review.Frontiers in pharmacology · 2026Review
- Anti-Cancer Research Progress of Triptolide: Mechanisms of Action, Structural Modifications, Nanodelivery Systems and Clinical Challenges.Drug design, development and therapy · 2026Review
- Article
- A comprehensive overview of triptolide utilizing nanotechnology and its potential applications in prostate diseases.Frontiers in pharmacology · 2025Review
- Current Insights into Therapeutic Potential of Terpenoids as Anticancer Agents.Anti-cancer agents in medicinal chemistry · 2025Review
- In Vivo and Clinical Studies of Natural Products Targeting the Hallmarks of Cancer.Handbook of experimental pharmacology · 2025Review
- Triptolide and its prodrug Minnelide target high-risk MYC-amplified medulloblastoma in preclinical models.The Journal of clinical investigation · 2024Article
- Triptolide suppresses IL-1β-induced expression of interleukin-8 by inhibiting ROS-Mediated ERK, AP-1, and NF-κB molecules in human gastric cancer AGS cells.Frontiers in oncology · 2024Article
- Transferrin-Modified Triptolide Liposome Targeting Enhances Anti-Hepatocellular Carcinoma Effects.Biomedicines · 2023Article
- Dual-Drug Delivery by Anisotropic and Uniform Hybrid Nanostructures: A Comparative Study of the Function and Substrate-Drug Interaction Properties.Pharmaceutics · 2023Review
- Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.Journal for immunotherapy of cancer · 2023Review
- Insights into the mechanisms of triptolide nephrotoxicity through network pharmacology-based analysis and RNA-seq.Frontiers in plant science · 2023Article
- The Anti-Inflammatory and Immunomodulatory Activities of Natural Products to Control Autoimmune Inflammation.International journal of molecular sciences · 2022Review
- Delivery of triptolide: a combination of traditional Chinese medicine and nanomedicine.Journal of nanobiotechnology · 2022Review
- Advances in the study of HSP70 inhibitors to enhance the sensitivity of tumor cells to radiotherapy.Frontiers in cell and developmental biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triptolide (TPL/TL) is a natural drug with novel anticancer effects. Preclinical studies indicated that TPL inhibits cell proliferation, induces cell apoptosis, inhibits tumor metastasis and enhances the effect of other therapeutic methods in various cancer cell lines. Multiple molecules and signaling pathways, such as caspases, heat-shock proteins, NF-κB, and deoxyribonucleic acid (DNA) repair-associated factors, are associated with the anti-cancer effect. TPL also improves chemoradiosensitivity in cancer therapy. Phase I trials indicate the potential clinical value of TPL use. However, further trials with larger sample sizes are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.